Glucose Tolerance and Insulin Release in Hypertensive Patients Treated with the Cardioselective β-Receptor Blocking Agent Metoprolol

2009 ◽  
Vol 202 (1-6) ◽  
pp. 393-397 ◽  
Author(s):  
Göran Ekberg ◽  
Bengt-Göran Hansson
Keyword(s):  
Glucose Tolerance ◽  
Insulin Release ◽  
Blocking Agent ◽  
Hypertensive Patients ◽  
Receptor Blocking ◽  
Β Receptor

Pharmacokinetics of β-Receptor-Blocking Agents in Relation to Their Anti-Hypertensive Effect

1976 ◽  
Vol 51 (s3) ◽  
pp. 473s-475s
Author(s):  
R. Gugler ◽  
G. Bodem ◽  
H. J. Dengler
Keyword(s):  
Liver Blood Flow ◽  
Systemic Availability ◽  
Receptor Blockade ◽  
Hypertensive Patients ◽  
Receptor Blocking ◽  
First Pass ◽  
High Doses ◽  
Β Receptor ◽  
Plasma Half Life ◽  
Propranolol Therapy

1. β-Receptor-blocking drugs are rapidly and completely absorbed after oral administration. Systemic availability is nevertheless incomplete for propranolol, alprenolol and oxprenolol, owing to ‘first-pass’ extraction by the liver. 2. Plasma half-life is between 2 and 4 h, except for sotalol (10–12 h). Plasma elimination of propranolol is reduced with decreased liver blood flow, observed in congestive heart failure or during chronic propranolol therapy itself. 3. β-Receptor blockade is usually achieved in these concentration ranges: propranolol and alprenolol, 50–100 ng/ml; oxprenolol, 500–1000 ng/ml; pindolol, 10–30 ng/ml; sotalol, 2–6 μg/ml. Higher concentrations are often found with high doses administered to hypertensive patients.

scholarly journals Hemodynamic Effects of an Adrenergic β-Receptor Blocking Agent, Kö1366 in Old Subjects

1977 ◽  
Vol 8 (4) ◽  
pp. 471-484
Author(s):  
Fujio TERASAWA ◽  
Masao IKEDA ◽  
Takaomi SUZUKI ◽  
Hon Ying LIE ◽  
Masuji SEKI
Keyword(s):  
Blocking Agent ◽  
Hemodynamic Effects ◽  
Receptor Blocking ◽  
Β Receptor
Sign in / Sign up

Export Citation Format

Share Document